PDCD1 and familial pancreatic carcinoma: Preclinical studies in subcutaneous and metastatic pancreatic cancer mouse models demonstrated that the combination of a T-cell vaccine, a PD-1 antagonist and a CD40 agonist mAb was able to eradicate most tumours, favouring antitumour immunity by reprogramming immune resistant tumours [201].